On 25 February 2021, Zhenzhen Chen will defend his PhD thesis on
Investigations into alternatives for sustainable control of psoroptic mange in Belgian blue cattle
Due to current Covid-19 measures, the defence will only be accessible online. If you wish to attend, please register by sending an email to Zhenzhen.Chen@UGent.be before 24 February 2021 to receive a personal invitation.
On 8 February 2021 at 4 p.m., Robert Jansens will defend his PhD thesis on
Taking Control Alphaherpesvirus Manipulation of the Cytoskeleton and the Epitranscriptome
Due to the Covid-19 measurements, the defence will be live streamed. If you wish to participate to the videoconference, please send an e-mail to firstname.lastname@example.org to receive a personal invitation.
The IABS-EU, in association with PROVAXS and Ghent University, hosted the “2 nd Conference on Next Generation Sequencing (NGS) for Adventitious Virus Detection in Human and Veterinary Biologics” held on November 13 th and 14 th 2019, in Ghent, Belgium. The meeting brought together international experts from regulatory agencies, the biotherapeutics and biologics industries, contract research organizations, and academia, with the goal to develop a scientific consensus on the readiness of NGS for detecting adventitious viruses, and on the use of this technology to supplement or replace/substitute the currently used assays. Participants discussed the progress on the standardization and validation of the technical and bioinformatics steps in NGS for characterization and safety evaluation of biologics, including human and animal vaccines. It was concluded that NGS can be used for the detection of a broad range of viruses, including novel viruses, and therefore can complement, supplement or even replace some of the conventional adventitious virus detection assays. Furthermore, the development of reference viral standards, complete and correctly annotated viral databases, and protocols for the validation and follow-up investigations of NGS signals is necessary to enable broader use of NGS. An international collaborative effort, involving regulatory authorities, industry, academia, and other stakeholders is ongoing toward this goal.
Please download the full report of the conference here:
On 27 November 2020, Bert Damiaans will defend his PhD thesis on
Investigating and quantifying biosecurity in Belgian cattle production
The defense will take place on Friday 27 November 2020 at 17h. Due to the current Covid-19 measures, the defense will only be accessible via live-stream. If you wish to participate in the videoconference, please register by sending an e-mail to email@example.com to receive a personal invitation.
Biocheck provides a unique risk-based scoring system to measure the level of biosecurity in pig, poultry and cattle farms.
Biocheck allows an easy and fast quantification of a farm’s biosecurity, which is key in animal disease prevention. Access to the system, which is marketed as a SaaS-based solution can be offered through an API.
Biocheck uses a calculation algorithm which takes into account all important risk factors, their frequency of occurrence, and interactions. It has been developed through years of scientific research and has been used and validated successfully in multiple studies pertaining to biosecurity.
Biocheck is unique in its kind, it is the only system available that provides a risk-based quantitative evaluation of biosecurity at farm-level.
Biocheck is continuously improved to stay in line with the most recent scientific insights. It has one of the largest databases, increasing continuously in size and global coverage, with biosecurity practices around the world. It has gathered international recognition as one of the most user-friendly and advanced systems of its kind.
Congratulations to Prof. Dr. Kristien van Reeth, member of PROVAXS, who participated with the award-winning presentation “Expanding anti-influenza antibody responses by heterologous prime-boost vaccination or “variations on a vaccine”” to the 3rd edition of the GSK Meets Belgian Universities Digital Event which was held on October 27, 2020.
Her presentation is a clear expample of how Cross Health research can lead to insights that are valuable for vaccine development in different species.
On August 2020, Lisse Vera will defend her PhD thesis on
Non-invasive determination of arterial wall stiffness for cardiovascular risk assessment in horses
The public defence will take place on Monday, 31 August at 16h30. Aula, Volderstraat 12, 9000 Ghent, Belgium. Due to the current Covid-19 measures, there will only be a limited number of seats available. Please contact Lisse Vera (firstname.lastname@example.org) if you like to attend the session on site. The defence will also be live streamed. If you like to participate in the online Teams videoconference, please send an e-mail (email@example.com) to receive a personal invitation.